Holen Sie sich die Stockscreener-App
461.93
3.80%
16.89
Handel nachbörslich:
461.93
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$445.04
Offen:
$448.79
24-Stunden-Volumen:
303.50K
Relative Volume:
0.88
Marktkapitalisierung:
$10.60B
Einnahmen:
$958.40M
Nettoeinkommen (Verlust:
$-288.28M
KGV:
-35.91
EPS:
-12.8641
Netto-Cashflow:
$-193.02M
1W Leistung:
+4.51%
1M Leistung:
+6.19%
6M Leistung:
+9.21%
1J Leistung:
+34.56%
1-Tages-Spanne:
$448.49
$471.72
1-Wochen-Bereich:
$437.05
$471.72
52-Wochen-Spanne:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
461.93 | 10.21B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Aug Selloffs: How correlated is Madrigal Pharmaceuticals Inc to the S P5002026 Price Momentum & AI Powered Market Trend Analysis - baoquankhu1.vn
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
Madrigal slides more than 5% as wider Q4 loss tempers strong sales growth - MSN
Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal grants inducement awards to five employees - MSN
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (MDGL) Movement - Stock Traders Daily
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Groupama Asset Managment Sells 13,447 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL Stock Price, Quote & Chart | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY - MarketBeat
Iron Triangle Partners LP Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
First Light Asset Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Baker BROS. Advisors LP - MarketBeat
32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC - MarketBeat
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC - MarketBeat
Madrigal Pharmaceuticals presence at Liver Connect Conference as attendance doubles - Traders Union
Avoro Capital Advisors LLC Cuts Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Is Rezdiffra’s Near‑US$1 Billion Debut Reshaping The Investment Case For Madrigal Pharmaceuticals (MDGL)? - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Reduces Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Pullback - simplywall.st
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
Madrigal Pharmaceuticals Grants Equity Awards to 20 New Employees - MyChesCo
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge? - Yahoo Finance
2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy - Finviz
Fieldview Capital Management LLC Invests $2.14 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Discipline and Rules-Based Execution in MDGL Response - Stock Traders Daily
Rhenman & Partners Asset Management AB Purchases Shares of 18,250 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Madrigal Pharmaceuticals EVP Dier sells $854k in stock - Investing.com
Madrigal Pharmaceuticals EVP Dier sells $854k in stock By Investing.com - Investing.com South Africa
Pharma News: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & High Accuracy Swing Entry Alerts - Naître et grandir
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $853,984.34 in Stock - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells $718,316.22 in Stock - MarketBeat
Market Review: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerPortfolio Update Summary & Stock Timing and Entry Methods - Naître et grandir
Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $155,498.40 in Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 491 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals CEO Sibold sells $718k in shares By Investing.com - Investing.com Canada
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):